# Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine

> **NCT01430442** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 1026 (actual)

## Conditions studied

- Migraine
- Acute Treatment of Migraine

## Interventions

- **DRUG:** Rimegepant
- **DRUG:** Placebo
- **DRUG:** Sumatriptan

## Key facts

- **NCT ID:** NCT01430442
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 1026 (ACTUAL)
- **Last updated:** 2023-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01430442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01430442, "Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01430442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*